The data indicated ERRγ signaling was associated with poor DMFS in ER+, TAM-treated breast cancer, suggesting hyper-activation or over-expression of ERRγ induces a pro-survival transcriptional program that impairs the ability of TAM to inhibit the growth of ER+ breast cancer [45]. The gene discussed is ESR1; the disease is breast carcinoma.